RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS ENCODING A HER-2 ANTIGEN IN COMBINATION WITH A TAXANE FOR USE IN TREATING CANCER

摘要

The invention relates to compositions, kits, and methods for cancer therapy using recombinant MVA viruses encoding a tumor-associated antigen, such as HER-2, particularly in combination with taxanes. The taxanes can be administered prior to, at the same time as, or after the recombinant MVA virus.